Context: Oncology workers are occupationally exposed to antineoplastic drugs. This exposure can induce adverse health effects. In order to reduce their exposure, contamination on surfaces should be kept as low as possible. Objectives: To monitor environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in oncology pharmacy and patient care areas in Canadian hospitals. To describe the impact of some factors that may limit contamination.
Introduction
Antineoplastic drugs are commonly used; in 2013, antineoplastic and immunomodulating agents represented 15% ($1.2/7.8 million CAD$) of public drug spending in Canada. 1 In Quebec, Canada, oncology drugs represented 38% of all drugs used in hospitals. 2 Safe handling procedures and protection equipment are necessary to protect health care professionals in contact with these drugs. Occupational exposure may lead to adverse health effects such as genotoxicity and reproductive risks. 3, 4 Dermal exposure occurs throughout 1 Pharmacy Department and Pharmacy Practice Research Unit, CHU Sainte-Justine, Montréal, Québec, Canada 2 Centre de toxicologie du Québec, Institut national de santé publique du Québec, Québec, Canada the drug use process when preparing and administering drugs. 5 Antineoplastic drug traces are found on the exterior surface of vials 6 and on many surfaces in contact with them, so precautions are necessary when receiving, transporting, or eliminating these drugs. The US National Institute for Occupational Safety and Health (NIOSH) was one of the first association to raise this issue and, since 2004, they frequently update a list of drugs that should be considered hazardous, including antineoplastic drugs. 7, 8 Environmental monitoring can be conducted to highlight contaminated areas and to describe the impact of organizational or equipment change. The Canadian Society of Hospital Pharmacists recommends environmental monitoring for hazardous drug to be performed at least annually. 9 Recommendations may vary by province. For example, in Quebec, periodic environmental monitoring is recommended both by the Association paritaire pour la sante´et la se´curited u travail du secteur des affaires sociales (ASSTSAS; on an annual basis and after organizational changes) and by the Ordre des Pharmaciens du Que´bec (every six months). 10, 11 As no health-based safe exposure limit is known, the surface contamination should be kept as low as reasonably achievable. Considering the large variation in contamination levels in various countries, and considering the constant improvement in working practices over the years, it is the authors' belief that any surface contamination goal or limit should be locally based and periodically updated.
In previous studies conducted over the years in Canadian hospitals, we observed that the surface contamination with antineoplastic drugs was reduced and maintained at a low level. [12] [13] [14] [15] Our hypothesis was that repeated participation in environmental monitoring studies helps maintaining a low level of surface contamination. In 2014, the Ordre des Pharmaciens du Que´bec published a guideline on sterile compounding of hazardous drugs. 11 One year after its publication, most Quebec hospitals have updated their procedures and equipment to meet this standard. We were also interested in finding out if it had an impact on surface contamination.
The aim of this study was to monitor environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in oncology pharmacy and patient care areas in Canadian hospitals. The secondary objective was to describe the impact of some factors that may limit contamination: repeated environmental monitoring, use of closed-system drug transfer devices, removal of outer packaging, cleaning of vials after receipt, and antineoplastic drugs usage.
Methods

Participating hospitals
Directors of pharmacy departments in Canadian hospitals with at least 50 acute care beds were contacted by e-mail on 6 Each participating hospital was expected to apply local policies and procedures for compounding, administration, surface cleaning, waste management, and other aspects of drug handling. All participating hospitals were equipped with laminar air flow cabinets in the pharmacy, for sterile compounding. Each hospital paid for their sample analysis.
Participants had to fill out a form describing their practice when receiving stock (i.e., removal of outer packaging and cleaning of the exterior of vials), their use of closed-system drug transfer devices and their antineoplastic usage. Unpacking and cleaning vials upon receipt are recommended by the Quebec association ASSTSAS and by the Ordre des Pharmaciens du Que´bec. 10, 11 After the study was completed, each participating center received a report comparing its results with global results from all participating centers. The authors' research group previously set the overall 75th percentile of surface concentration as a goal for every participating center; after the conclusion of the study, centers were encouraged to target sampling sites with values above this goal for corrective measures.
Sampling technique
Twelve standardized sampling sites, six in pharmacy areas and six in patient care areas, were selected, consistent with previous studies. [12] [13] [14] [15] For nearby hospitals, samples were collected by one research assistant. For remote hospitals, they were collected by a trained employee from the participating hospital. A video of the sampling technique was provided for training of employees and participating hospitals were given a description and photographs of the standardized sampling sites. Sampling occurred at the end of a work day or in the morning, before the room was cleaned.
For each sample, a standardized surface of about 600 cm 2 (20 cm Â 30 cm) was sampled with one 6 cm Â 8 cm 
Analytical procedure
Sampling wipes were stored between 2 C and 8 C in 50-ml polypropylene tubes. Prior to analysis, 10 ml of extracting solution and internal standards were added to each tube. Tubes were mechanically stirred for 10 min, and an aliquot of the solution was used for analysis. For each sample, three antineoplastic drugs (cyclophosphamide, ifosfamide, methotrexate) were quantified by ultra performance liquid chromatography tandem mass spectrometry UPLC-MS-MS (Acquity UPLC chromatographic system coupled with Xevo TQ-S tandem mass spectrometer; Waters, Milford, Massachusetts, USA). Chromatography was carried out on a C18 Acquity UPLC BEH column (2.1 Â 50 mm, 1.7 mm; Waters, Milford, Massachusetts, USA) using an increasing gradient from 10/90 methanol/5 mM ammonium acetate to 60/40 methanol/5 mM ammonium acetate in 2 min. Recovery from surfaces was described previously. 15 Results were expressed in ng/ml and converted to ng/cm 2 . Final results were expressed in pg/cm 2 . The limit of detection was 0.36 pg/cm 2 (19.8 pg/ml) for cyclophosphamide, 0.95 pg/cm 2 (52 pg/ml) for ifosfamide, and 0.97 pg/cm 2 (53 pg/ml) for methotrexate. The limit of quantification was 1.21 pg/cm 2 (65.9 pg/ ml) for cyclophosphamide, 3.17 pg/cm 2 (173 pg/ml) for ifosfamide, and 3.25 pg/cm 2 (177 pg/ml) for methotrexate. The limit of detection was used as the reporting limit.
Data analysis
The proportion of positive samples was calculated. A sample was considered positive for a particular drug if the value was above the limit of detection and if the quantifier peak was within the maximum tolerance of mean calibrator for confirmatory criteria (signal/noise ratio > 3, retention time AE 0.02 min, quantifier/qualifier ion ratio AE 20%). Descriptive statistical analyses (minimum, mean, standard deviation, median, 75th percentile, 90th percentile, maximum) were carried out with PASW Statistics 17.0 (SPSS Inc., Quarry Bay, Hong Kong). For calculations, concentrations that fell between the limit of detection and the limit of quantification were assigned a value corresponding to the limit of quantification divided by 2, 17 and concentrations that fell below the limit of detection were assigned a value corresponding to the limit of detection divided by 2.
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Subanalyses were performed according to hospitals' working practices and antineoplastic drugs usage. The effect of having participated to the four previous environmental monitoring studies was also evaluated.
Results were compared with a Kolmogorov-Smirnov test for independent samples. A p value less than 0.05 was considered significant. For these subanalyses, only the results for cyclophosphamide contamination were used, as they were deemed representative of the current situation; there was too little surface contamination with ifosfamide and methotrexate to allow similar subanalyses.
Results
Participating hospitals
Forty-eight Canadian hospitals participated in 2015 (response rate 23.8%, 48/202). The majority was from Quebec (75.0%, 36/48). Other participating hospitals were from Ontario (n ¼ 6), Manitoba (n ¼ 2), Saskatchewan (n ¼ 2), Nova Scotia (n ¼ 1), and Newfoundland and Labrador (n ¼ 1).
Over the period 1 April 2014 to 31 March 2015, participating hospitals performed a median (minimum-maximum) of 6165 (81-62,664) antineoplastic drugs preparations (n ¼ 40). Nineteen hospitals prepared less than 5000 preparations per year (47.5%), 10 between 5000 and 15,000 (25.0%), and 11 more than 15,000 (27.5%). A higher proportion of respondents from other provinces (7/10, 70.0%) prepared less than 5000 preparations per year compared with Quebec respondents (12/30, 40.0%). Respondents used, in grams per year, 307 (0-2700) of cyclophosphamide (n ¼ 45), 25 (0-970) of ifosfamide (n ¼ 45), and 8 (0-750) of methotrexate (n ¼ 45). Twenty-eight hospitals (62.2%) used less than 500 g of cylophosphamide, 10 between 500 and 1000 (22.2%) and 7 more than 1000 (15.6%). Again, a higher proportion of respondents from other provinces (8/10, 80.0%) used less than 500 g of cyclophosphamide per year compared with respondents from Quebec (20/35, 57.1%).
A quarter of participating hospitals used a closedsystem drug transfer device (26.1%, 12/46), less in (Tables 1-3 ). The overall proportion of cyclophosphamide positive samples was slightly higher in Quebec hospitals (37.0%, 150/405) compared with hospitals from other provinces (25.8%, 31/120). Respondents had a similar proportion of cyclophosphamide positive samples in pharmacy (38.5%, 82/213 for Quebec and 24.6%, 17/69 for other provinces) and in patient care areas (35.4%, 68/192, and 27.5%, 14/51). The majority (more than 50%) of samples had traces of cyclophosphamide on the front grille of the hood, the floor in front of the hood, and on the arm rest. Max: maximum; perc.: percentile; SD: standard deviation; LOD: limit of detection. A sample was considered positive if it was above the limit of detection. The limit of detection was of 0.97 pg/cm 2 (53 pg/ml) for methotrexate. Max: maximum; perc.: percentile; SD: standard deviation; LOD: limit of detection. A sample was considered positive if it was above the limit of detection. The limit of detection was of 0.95 pg/cm 2 (52 pg/ml) for ifosfamide.
The 75th percentile of cyclophosphamide on surfaces was 6.9 pg/cm 2 and it was lower than the limit of detection for ifosfamide and methotrexate (Tables 1-3) . In Quebec hospitals, the 75th percentile of cyclophophamide concentration was higher in pharmacy (9.5 pg/ cm 2 ) than in patient care areas (6.0 pg/cm 2 ). Inversely, for hospitals from other provinces, the contamination was lower in pharmacy (1.2 pg/cm 2 ) than in patient care areas (2.5 pg/cm 2 ). The overall 75th percentile of surface concentration was also higher in Quebec hospitals (8.5 pg/cm 2 ) compared with hospitals from other provinces (2.0 pg/cm 2 ), but this difference was not significant (p ¼ 0.196). The highest concentrations were found on the exterior surface of an antineoplastic drug container (130,000 pg/cm 2 for cyclophosphamide), on an arm rest (440 pg/cm 2 for ifosfamide) and on a storage shelf (7 300 pg/cm 2 for methotrexate).
Impact of practices
Eighteen centers from Quebec participated in all five studies conducted since 2008. Seven centers from other provinces participated for the second time (recruitment for other provinces was only opened in 2014). No significant difference was found between centers who participated in all five studies and other centers (Table 4) . There was no significant difference in centers who used closed-system drug transfer devices, who removed the outer packaging of drugs and who cleaned the exterior of vials after receipt. Centers who prepared more antineoplastic drugs per year and centers who used more cyclophosphamide per year showed significantly higher surface contamination. It should be noted that the second highest cyclophosphamide contamination (11,000 pg/cm 2 ) was found in a hospital who performed less than 5000 antineoplastic drug preparations per year and who used less than 500 g of cyclophosphamide per year. The other four highest cyclophosphamide contamination values were also found in hospitals who used less than 500 g of cyclophosphamide per year.
Trends
In this 2015 study, we observed that both the proportion of cyclophosphamide positive samples and the 75th percentile of surface concentration were reduced (Figure 1(a) and (b) ). This reduction was also observed with ifosfamide and methotrexate.
Discussion
Environmental monitoring
This Canadian multicenter study was conducted for the fifth time. A good participation rate was obtained, especially for Quebec centers (75.0%). A third of the samples was positive for cyclophosphamide (34.4%) and approximately 10% was positive for ifosfamide (7.8%) and methotrexate (5.9%). Surface concentration remained low; the 75th percentile was of 6.9 pg/ cm 2 for cyclophosphamide and it was below the limit of detection for ifosfamide and methotrexate. The sampling sites that were the most frequently contaminated were the front grille of the hood, the floor in front of the hood, and the arm rest.
Impact of practices
We observed a reduction in surface contamination in 2015. As participating hospitals had different storage, preparation, and administration procedures, multiple factors may explain this reduction. We did not see a significant reduction in the overall contamination for hospitals who used closed-system drug transfer devices, removed the outer packaging, and cleaned vials after receipt. Closed-system drug transfer devices have been shown to reduce surface contamination in pre-post implementation studies. 19, 20 It is difficult to rule out the effect of time and of an increased awareness of workers in the improvement observed in these studies. It was interesting to notice that low contamination levels were observed in our study even for centers who did not use closed-system drug transfer devices; this implies that other less costly good working practices can be implemented to reduce environmental contamination.
The impact of removing the outer packaging and cleaning vials upon receipt was also evaluated because these practices are not costly and can limit the exterior of the commercial vials as a source of contamination. Even though this practice was not associated with a significant reduction in contamination, washing the vials is a simple solution that can be easily implemented. It may also limit a workers exposure, considering that gloves are not always worn when handling vials during receipt and storage.
This descriptive study was conducted in many different settings, so the study design did not allow us to distinguish the impact of one given practice.
We found higher concentrations on surfaces of hospitals who reported higher antineoplastic drug usage. Nonetheless, some of the most contaminated sites were found in hospitals with a lower number of antineoplastic drug preparations per year, so safe handling procedures need to be established everywhere they are used. Recently, Odraska et al., 21 have also shown that centers with a higher number of chemotherapies prepared per week were more contaminated. Many factors may explain contamination; high levels of contaminations were probably caused by a lack of cleaning frequency or efficacy or by an accidental spill. It should be reminded that sampling for this study was performed after a workday before thorough cleaning was done.
The 18 centers that participated in the five studies conducted since 2008 did not show a reduced contamination compared with hospitals that participated in less than five studies. Nevertheless, the overall contamination was reduced in 2015, when compared with previous studies. [12] [13] [14] [15] Other authors have reported that repeated environmental monitoring leads to improvement in surface contamination. For example, Sottani et al., 22 have shown a marked improvement in surface cyclophosphamide contamination in five Italian hospitals over a 10-year period.
It is also probable that the majority of participating hospitals from Quebec improved their practices in order to meet the new Ordre des Pharmaciens du Que´bec standard on sterile compounding of hazardous drugs. 11 Less contamination was observed in the 12 centers from other provinces, even though this difference was not significant. The majority of these hospitals participated for a second year in a row. A marked improvement was observed for Quebec hospitals the second year the study was conducted, so this effect may have been part of the reason the overall contamination was reduced. Furthermore, hospitals from other provinces had a lower antineoplastic drug usage, which probably contributed to this lower contamination.
Some participants mentioned their interest in other hazardous drugs more frequently used in their center (e.g., gemcitabine, 5-fluorouracil, platin). For future environmental monitoring studies, our research group will be looking at either adding or replacing some drugs to improve the monitoring of the current level of contamination.
Surface contamination goal
As long as no health-based safe exposure limit is known, there is a large variation in the contamination levels seen in various countries in the literature and best practices are constantly evolving, we believe that any surface contamination goal should be locally based and periodically updated. We suggest that conducting regular environmental monitoring helps maintaining a high level of awareness for workers. It can help identifying problematic areas. Centers can then put their results in perspective with those of others and evaluate to what extent resources need to be allocated to corrective measures. In any cases, personal protective equipment remains of the utmost importance for the safety of workers.
Strengths
A high number of centers from Canada participated in this study. The variability in hospital settings did not allow us to detect the effect of individual working practices, but it allowed for an excellent representation of the actual surface contamination. Many articles on environmental contamination are conducted in a study setting and any improvement observed may be biased by a cross-sectional improvement due to the study context.
We showed that, throughout the years, a low level of contamination was observed in a high number of Canadian hospitals; this result is encouraging, given the absence of safe contamination levels.
Limits
The cost of the analysis may have prevented some hospitals from participating. Some hospitals mentioned they were hesitant to participate again, considering budget cuts and low surface contamination. Interestingly, a few of these had worse results than previous years and did appreciate this annual feedback to help maintain a high level of awareness and good practices among their staff. While the participation cost is not little (i.e., 780$ CAD/year), it is certainly much less than the use of closed-system drug transfer devices.
Sampling was performed on a single day in each center; different results might have been obtained on a different day. Nonetheless, sampling was performed before the rooms were cleaned.
Subanalysis was performed to describe a possible impact of some working practices, but was not the object of a rigorous controlled environment, so bias should be taken into account.
Conclusion
The conduct of environmental monitoring is an opportunity to increase workers' awareness on the issue of occupational exposure. Problematic areas can be identified and efforts can be made to modify working practices or to improve cleaning methods. Over the years, we observed that the concentration of antineoplastic drugs measured on hospital surfaces in Canada is decreasing. However, some sites are still frequently contaminated. Regular environmental monitoring is a good practice to maintain contamination as low as reasonably achievable. As long as no health-based limit is known, we are encouraging centers to monitor their contamination. Local goals should be set to reinforce the need for continuous efforts.
